KELYB vs RTX

KELYB exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, placing it firmly in the 'Weak' health category. While the stock appears undervalued on a Price-to-Book (0.55) and Price-to-Sales (0.13) basis, this is likely a value trap given the negative profit margins (-5.98%) and contracting revenue (-11.90%). The combination of a negative ROE (-22.98%) and significant insider selling suggests a deteriorating business model. Despite a recent 1-year price recovery, the long-term 5-year trend remains deeply negative (-43.5%).

RTX exhibits stable financial health with a Piotroski F-Score of 5/9, yet it is trading at a severe premium compared to its Graham Number ($73.73) and Intrinsic Value ($96.67). While the company boasts an exceptional track record of earnings beats over 25 quarters and solid revenue growth, the valuation is stretched with a PEG ratio of 2.75. This fundamental overvaluation is compounded by bearish insider sentiment and a weak technical trend, suggesting that while the business is strong, the stock price is currently decoupled from its deterministic value.